熱門資訊> 正文
Predictive Oncology希望通过行使认购证筹集130万美元
2024-07-26 20:05
- Predictive Oncology (NASDAQ:POAI) said will exercise certain existing warrants to purchase an aggregate of 958.1K shares of its common stock, having a current exercise price of $14.
- The warrants were originally issued in February 2021, June 2021 and May 2022, at a reduced exercise price of $1.32 per share.
- The gross proceeds from the exercise of the existing warrants are expected to be ~$1.26 million.
More on Predictive Oncology
- Predictive Oncology gains, to present positive results from a retrospective study
- Predictive Oncology stock rallies 30% post-market on vaccine collaboration
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
